List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/142876/publications.pdf Version: 2024-02-01

		81743	118652
197	5,486	39	62
papers	citations	h-index	g-index
213	213	213	7557
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Environmental Mycobacteria. , 2022, , 515-522.		0
2	Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features. Molecular and Cellular Biochemistry, 2022, 477, 711-726.	1.4	14
3	Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity. Peptides, 2022, 150, 170716.	1.2	7
4	Bilateral pneumonectomy and lung transplant for COVID–19-induced respiratory failure. JTCVS Techniques, 2022, , .	0.2	1
5	Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review. Pulmonary Therapy, 2022, 8, 43-55.	1.1	9
6	Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804644.	1.8	40
7	Diagnostic Accuracy of Rapid Antigen Tests for COVID-19 Detection: A Systematic Review With Meta-analysis. Frontiers in Medicine, 2022, 9, 870738.	1.2	16
8	COVID-19 and Acute Kidney Injury: A Systematic Review. Frontiers in Medicine, 2022, 9, 705908.	1.2	45
9	Pulmonary manifestations of autoimmune diseases. , 2022, , 265-294.		0
10	Anti-inflammatory Properties of the Alpha-Melanocyte-Stimulating Hormone in Models of Granulomatous Inflammation. Lung, 2022, 200, 463-472.	1.4	3
11	SARS-CoV-2 cell entry beyond the ACE2 receptor. Molecular Biology Reports, 2022, 49, 10715-10727.	1.0	29
12	Effect of Face Masks on Gas Exchange in Healthy Persons and Patients with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2021, 18, 541-544.	1.5	73
13	Longâ€ŧerm exposure to indoor air pollution and risk of tuberculosis. Indoor Air, 2021, 31, 628-638.	2.0	7
14	Sarcoidosis or cancer? That is the question. Respiratory Medicine Case Reports, 2021, 33, 101426.	0.2	3
15	Activity of the growth hormoneâ€releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosisâ€like granuloma. Clinical and Translational Immunology, 2021, 10, e1310.	1.7	8
16	Antifibrotic and Anti-Inflammatory Actions of α-Melanocytic Hormone: New Roles for an Old Player. Pharmaceuticals, 2021, 14, 45.	1.7	17
17	Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Scientific Reports, 2021, 11, 3455.	1.6	71
18	Novel three-dimensional biochip pulmonary sarcoidosis model. PLoS ONE, 2021, 16, e0245805.	1.1	4

#	Article	IF	CITATIONS
19	Skin Manifestations in COVID-19 Patients: Are They Indicators for Disease Severity? A Systematic Review. Frontiers in Medicine, 2021, 8, 634208.	1.2	42
20	Phage Therapy for Mycobacterium Abscessus and Strategies to Improve Outcomes. Microorganisms, 2021, 9, 596.	1.6	11
21	The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review. Frontiers in Endocrinology, 2021, 12, 645194.	1.5	37
22	Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirusÂ2): diagnosis, treatment, therapy and future perspectives. Nanomedicine, 2021, 16, 497-516.	1.7	61
23	Perspectives on the Health Effects of Hurricanes: A Review and Challenges. International Journal of Environmental Research and Public Health, 2021, 18, 2756.	1.2	37
24	Allergies, Allergic Comorbidities and the Home Environment in Pediatric Asthma in Southern Florida. International Journal of Environmental Research and Public Health, 2021, 18, 4142.	1.2	6
25	Role of Clofazimine in Treatment of Mycobacterium avium Complex. Frontiers in Medicine, 2021, 8, 638306.	1.2	9
26	Associations of Yersinia Enterocolitica Infection with Autoimmune Thyroid Diseases: A Systematic Review and Meta-Analysis. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 682-687.	0.6	10
27	Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America. Viruses, 2021, 13, 930.	1.5	13
28	State-Level Health Disparity Is Associated with Sarcoidosis Mortality. Journal of Clinical Medicine, 2021, 10, 2366.	1.0	5
29	COVID-19 and Cardiomyopathy: A Systematic Review. Frontiers in Cardiovascular Medicine, 2021, 8, 695206.	1.1	21
30	Nontuberculous Mycobacteria, Macrophages, and Host Innate Immune Response. Infection and Immunity, 2021, 89, e0081220.	1.0	25
31	A Trend Analysis of Chronic Obstructive Pulmonary Disease Mortality in the United States by Race and Sex. Annals of the American Thoracic Society, 2021, 18, 1138-1146.	1.5	16
32	Inborn Errors in the LRR Domain of Nod2 and Their Potential Consequences on the Function of the Receptor. Cells, 2021, 10, 2031.	1.8	3
33	Mask-off policy in the shadow of emerging variants of SARS-COV-2. European Journal of Internal Medicine, 2021, 90, 109-110.	1.0	1
34	COVID-19 and cause of pregnancy loss during the pandemic: A systematic review. PLoS ONE, 2021, 16, e0255994.	1.1	45
35	Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Mycobacterium avium Complex: A meta-Analysis Study. Frontiers in Pharmacology, 2021, 12, 693369.	1.6	3
36	Diagnostic Accuracy of Pyrazinamide Susceptibility Testing in Mycobacterium tuberculosis: A Systematic Review with Meta-Analysis. Microbial Drug Resistance, 2021, , .	0.9	1

#	Article	IF	CITATIONS
37	Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. Frontiers in Medicine, 2021, 8, 731436.	1.2	40
38	Commentary: Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. Frontiers in Medicine, 2021, 8, 747109.	1.2	0
39	Machine-learning-based COVID-19 mortality prediction model and identification of patients at low and high risk of dying. Critical Care, 2021, 25, 328.	2.5	59
40	A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPOSITORY CORTICOTROPIN INJECTION IN SUBJECTS WITH PULMONARY SARCOIDOSIS (PULSAR): STUDY DESIGN AND BASELINE CHARACTERISTICS. Chest, 2021, 160, A1271-A1272.	0.4	1
41	Pulmonary nontuberculous mycobacterial disease in Florida and association with large-scale natural disasters. BMC Public Health, 2021, 21, 2058.	1.2	6
42	Crosstalk Between Gut and Brain via Neurotransmitters. , 2021, , 49-70.		0
43	Effects of 100 % oxygen during exercise in patients with interstitial lung disease. Respiratory Physiology and Neurobiology, 2020, 274, 103367.	0.7	7
44	Potential Mechanisms for COVID-19 Induced Anosmia and Dysgeusia. Frontiers in Physiology, 2020, 11, 1039.	1.3	27
45	Management of crash and burn patients with SARS oVâ€2 associated ARDS. Journal of Cardiac Surgery, 2020, 35, 2129-2130.	0.3	0
46	Missense (p.Glu778Lys) and (p.Gly908Arg) variants of NOD2 gene are associated with recurrent pulmonary nonâ€ŧuberculous mycobacterial infections. Scandinavian Journal of Immunology, 2020, 92, e12935.	1.3	4
47	<p>Ocular Manifestations of Sarcoidosis in a South Florida Population</p> . Clinical Ophthalmology, 2020, Volume 14, 3741-3746.	0.9	2
48	COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis. Frontiers in Medicine, 2020, 7, 459.	1.2	110
49	Association between African Dust Transport and Acute Exacerbations of COPD in Miami. Journal of Clinical Medicine, 2020, 9, 2496.	1.0	6
50	Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease. Cells, 2020, 9, 2331.	1.8	18
51	Lack of tocilizumab effect on mortality in COVID19 patients. Scientific Reports, 2020, 10, 17100.	1.6	13
52	Olfactory and gustatory dysfunction in COVIDâ€19 patients: A metaâ€analysis study. Physiological Reports, 2020, 8, e14578.	0.7	40
53	State-Level Disparity in Lung Cancer Survival in the United States. Frontiers in Oncology, 2020, 10, 1449.	1.3	5
54	Presence of concurrent sarcoid-like granulomas indicates better survival in cancer patients: a retrospective cohort study. ERJ Open Research, 2020, 6, 00061-2020.	1.1	15

#	Article	IF	CITATIONS
55	Protective effect of influenza vaccination on cardiovascular diseases: a systematic review and meta-analysis. Scientific Reports, 2020, 10, 20656.	1.6	18
56	Prevalence and Mechanisms of Carbapenem Resistance in <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> : A Systematic Review and Meta-Analysis of Cross-Sectional Studies from Iran. Microbial Drug Resistance, 2020, 26, 1491-1502.	0.9	18
57	Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series. Frontiers in Medicine, 2020, 7, 231.	1.2	43
58	Anti-inflammatory effects of α-MSH through p-CREB expression in sarcoidosis like granuloma model. Scientific Reports, 2020, 10, 7277.	1.6	23
59	STAT3 gain-of-function mutation in a patient with pulmonary Mycobacterium abscessus infection. Respiratory Medicine Case Reports, 2020, 30, 101125.	0.2	8
60	Health and Economy in COVID-19 Era: A Plan for Reconstituting Long-Term Economic Security. Frontiers in Public Health, 2020, 8, 235.	1.3	14
61	The COVIDâ€19 Pandemic—Can open access modeling give us better answers more quickly?. Journal of Applied Clinical Medical Physics, 2020, 21, 4-6.	0.8	3
62	Association of Serum Albumin and Severity of Pulmonary Embolism. Medicina (Lithuania), 2020, 56, 26.	0.8	16
63	Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study. European Respiratory Review, 2020, 29, 190147.	3.0	11
64	Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. European Respiratory Review, 2020, 29, 190146.	3.0	92
65	Editorial: Interstitial Lung Disease in the Context of Systemic Disease: Pathophysiology, Treatment and Outcomes. Frontiers in Medicine, 2020, 7, 644075.	1.2	2
66	Antibiotic therapy success rate in pulmonary Mycobacterium avium complex: a systematic review and meta-analysis. Expert Review of Anti-Infective Therapy, 2020, 18, 263-273.	2.0	15
67	A First Look at the Italian Registry on Pulmonary Non-Tuberculous Mycobacteria (NTM) -IRENE. , 2020, , .		Ο
68	Improving survival outcome among elderly lung transplant recipients. European Journal of Internal Medicine, 2020, 74, 121-124.	1.0	0
69	Growth hormone releasing hormone-receptor antagonist MIA-602 modulates lung inflammation, cellular signal transduction, and promotes apoptosis of mouse lung fibroblasts. , 2020, , .		Ο
70	2-Year survival of patients with IPF with or without GERD: a study using VA national database. , 2020, , .		0
71	Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin. Lung, 2019, 197, 541-549.	1.4	29
72	The Importance of Melanocortin Receptors and Their Agonists in Pulmonary Disease. Frontiers in Medicine, 2019, 6, 145.	1.2	25

#	Article	IF	CITATIONS
73	Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease. Journal of Medical Economics, 2019, 22, 1126-1133.	1.0	8
74	An update on IgG4-related lung disease. European Journal of Internal Medicine, 2019, 66, 18-24.	1.0	35
75	Electronic Cigarettes Enhance Replication ofMycobacterium abscessusin Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 717-719.	1.4	5
76	Hepatic Sarcoidosis: Natural History and Management Implications. Frontiers in Medicine, 2019, 6, 232.	1.2	29
77	Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management. Frontiers in Medicine, 2019, 6, 248.	1.2	13
78	Mycobacterium abscessus—Bronchial Epithelial Cells Cross-Talk Through Type I Interferon Signaling. Frontiers in Immunology, 2019, 10, 2888.	2.2	17
79	Low diagnostic accuracy of Xpert MTB/RIF assay for extrapulmonary tuberculosis: A multicenter surveillance. Scientific Reports, 2019, 9, 18515.	1.6	32
80	Metabolomic and metallomic profile differences between Veterans and Civilians with Pulmonary Sarcoidosis. Scientific Reports, 2019, 9, 19584.	1.6	13
81	Mycobacterium aviumcomplex infection in patients with human immunodeficiency virus: A systematic review and metaâ€analysis. Journal of Cellular Physiology, 2019, 234, 9994-10001.	2.0	8
82	Rescue therapy for hypercapnia due to high PEEP mechanical ventilation in patients with ARDS and renal failure. Artificial Organs, 2019, 43, 599-604.	1.0	8
83	The unexplained increase of nontuberculous mycobacteriosis. International Journal of Mycobacteriology, 2019, 8, 1.	0.3	39
84	Serum Albumin as a Biomarker of Pulmonary Sarcoidosis Chronicity. Turkish Thoracic Journal, 2019, 20, 236-240.	0.2	1
85	The low prevalence of pulmonary embolism in patients with syncope: What should clinicians do?. American Journal of Emergency Medicine, 2018, 36, 1917-1918.	0.7	Ο
86	<i>rpoB</i> gene mutations among <i>Mycobacterium tuberculosis</i> isolates from extrapulmonary sites. Apmis, 2018, 126, 241-247.	0.9	4
87	A portrait of patients who die in-hospital from acute pulmonary embolism. American Journal of Emergency Medicine, 2018, 36, 1914-1916.	0.7	0
88	Lung health in era of climate change and dust storms. Environmental Research, 2018, 163, 36-42.	3.7	95
89	Hypoalbuminemia is related to inflammation rather than malnutrition in sarcoidosis. European Journal of Internal Medicine, 2018, 53, e14-e16.	1.0	17
90	Mycobacterium ahvazicum sp. nov., the nineteenth species of the Mycobacterium simiae complex. Scientific Reports, 2018, 8, 4138.	1.6	3

#	Article	IF	CITATIONS
91	Noncoding RNAs: New Players in Pulmonary Medicine and Sarcoidosis. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 147-156.	1.4	24
92	Syncope on presentation is a surrogate for submassive and massive acute pulmonary embolism. American Journal of Emergency Medicine, 2018, 36, 297-300.	0.7	11
93	Increasing Non-tuberculous Mycobacteria Infections in Veterans With COPD and Association With Increased Risk of Mortality. Frontiers in Medicine, 2018, 5, 311.	1.2	20
94	Impact of seasonal variation in meteorological conditions on dry eye severity. Clinical Ophthalmology, 2018, Volume 12, 2471-2481.	0.9	15
95	Prevalence of nontuberculous mycobacteria and high efficacy of D-cycloserine and its synergistic effect with clarithromycin against Mycobacterium fortuitum and Mycobacterium abscessus . Infection and Drug Resistance, 2018, Volume 11, 2521-2532.	1.1	21
96	Diagnosis of nontuberculous mycobacterial disease in the era of surveillance chest CT scans. Infection, 2018, 46, 861-865.	2.3	0
97	Differences in vaping topography in relation to adherence to exclusive electronic cigarette use in veterans. PLoS ONE, 2018, 13, e0195896.	1.1	14
98	A Young Woman with Bradycardia and Hypotension. Annals of the American Thoracic Society, 2018, 15, 1092-1095.	1.5	1
99	White donor, younger donor and double lung transplant are associated with better survival in sarcoidosis patients. Scientific Reports, 2018, 8, 6968.	1.6	6
100	The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. Multidisciplinary Respiratory Medicine, 2018, 13, 33.	0.6	10
101	Health Care Utilization and Expenditures Following Diagnosis of Nontuberculous Mycobacterial Lung Disease in the United States. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 964-974.	0.5	15
102	Mycobacterium avium Complex Extracellular Vesicles Attenuate Inflammation via Inducing IL-10. International Journal of Molecular and Cellular Medicine, 2018, 7, 241-250.	1.1	1
103	Circulatory TGF-beta1 is significantly higher in early stage of pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 213-217.	0.2	2
104	Patients at high risk of tuberculosis recurrence. International Journal of Mycobacteriology, 2018, 7, 1.	0.3	40
105	What Immunological Defects Predispose to Non-tuberculosis Mycobacterial Infections?. Iranian Journal of Allergy, Asthma and Immunology, 2018, 17, 100-109.	0.3	15
106	Recurrent Drug-Induced Hepatitis in Tuberculosis—Comparison of Two Drug Regimens. American Journal of Therapeutics, 2017, 24, e144-e149.	0.5	2
107	Bovis Bacillus Calmette–Guerin (BCG) infection induces exosomal miRNA release by human macrophages. Journal of Translational Medicine, 2017, 15, 105.	1.8	51
108	A Patient-Based Analysis of the Geographic Distribution of Mycobacterium avium complex, Mycobacterium abscessus , and Mycobacterium kansasii Infections in the United States. Chest, 2017, 151, 947-950.	0.4	23

#	Article	IF	CITATIONS
109	Mixed infections in tuberculosis: The missing part in a puzzle. Tuberculosis, 2017, 107, 168-174.	0.8	31
110	Sarcoidosis onset after breast cancer; a potential association. European Journal of Internal Medicine, 2017, 44, e11-e12.	1.0	12
111	Toll-like receptors in mycobacterial infection. European Journal of Pharmacology, 2017, 808, 1-7.	1.7	20
112	Cardiovascular complications and mortality determinants in near drowning victims: A 5-year retrospective analysis. Journal of Critical Care, 2017, 37, 237-239.	1.0	9
113	A risky political game with climate change. European Respiratory Journal, 2017, 50, 1701145.	3.1	2
114	Improving adherence to alpha-1 antitrypsin deficiency screening guidelines using the pulmonary function laboratory. International Journal of COPD, 2017, Volume 12, 2257-2259.	0.9	2
115	Mycobacterium aquaticum sp. nov., a rapidly growing species isolated from haemodialysis water. International Journal of Systematic and Evolutionary Microbiology, 2017, 67, 3279-3282.	0.8	11
116	Body habitus in patients with and without bronchiectasis and non-tuberculous mycobacteria. PLoS ONE, 2017, 12, e0185095.	1.1	11
117	The Association between ESR and CRP and Systemic Hypertension in Sarcoidosis. International Journal of Hypertension, 2016, 2016, 1-8.	0.5	16
118	Exosomes and Exosomal miRNA in Respiratory Diseases. Mediators of Inflammation, 2016, 2016, 1-11.	1.4	106
119	Management of extrapulmonary sarcoidosis: challenges and solutions. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1623-1634.	0.9	66
120	Microbiological Analysis of Hemodialysis Water in a Developing Country. ASAIO Journal, 2016, 62, 332-339.	0.9	13
121	Duration of ECMO Is an Independent Predictor of Intracranial Hemorrhage Occurring During ECMO Support. ASAIO Journal, 2016, 62, 634-636.	0.9	52
122	The simultaneous recording of right- and left-sided electrocardiogram in acute pulmonary embolism. American Journal of Emergency Medicine, 2016, 34, 1183.e5-1183.e7.	0.7	0
123	High prevalence of Mycobacterium tuberculosis mixed infection in the capital of moderate tuberculosis incidence country. Microbial Pathogenesis, 2016, 93, 213-218.	1.3	16
124	Annexins family: insights into their functions and potential role in pathogenesis of sarcoidosis. Journal of Translational Medicine, 2016, 14, 89.	1.8	80
125	The roles of miRNAs as potential biomarkers in lung diseases. European Journal of Pharmacology, 2016, 791, 395-404.	1.7	116
126	Climate Change and Respiratory Infections. Annals of the American Thoracic Society, 2016, 13, 1223-1230.	1.5	136

#	Article	IF	CITATIONS
127	Reply: Metabolomics and Mycobacterial Disease: Don't Forget the Bioinformatics. Annals of the American Thoracic Society, 2016, 13, 142-143.	1.5	0
128	Haarlem 3 is the predominant genotype family in multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in the capital of Iran: A 5-year survey. Journal of Global Antimicrobial Resistance, 2016, 5, 7-10.	0.9	14
129	Incidence and predictors of ischemic cerebrovascular stroke among patients on extracorporeal membrane oxygenation support. Journal of Critical Care, 2016, 32, 48-51.	1.0	43
130	<i>In Vitro</i> Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran. Microbial Drug Resistance, 2016, 22, 172-178.	0.9	31
131	Association of Neutrophil to Lymphocyte Ratio and Pulmonary Hypertension in Sarcoidosis Patients. Tanaffos, 2016, 15, 44-7.	0.5	7
132	Plasma metabolomic profile in fibrosing pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2016, 33, 29-38.	0.2	12
133	The association between BNP, 6MWD test, DLCO% and pulmonary hypertension in sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2016, 33, 317-320.	0.2	12
134	Annexin A11 is associated with pulmonary fibrosis in African American patients with sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2016, 33, 418-422.	0.2	6
135	Racial Difference in Sarcoidosis Mortality in the United States. Chest, 2015, 147, 438-449.	0.4	174
136	Response. Chest, 2015, 147, e65-e66.	0.4	0
137	Response. Chest, 2015, 147, e158-e159.	0.4	0
138	Genetic diversity and antimicrobial susceptibility of Nocardia species among patients with nocardiosis. Scientific Reports, 2015, 5, 17862.	1.6	53
139	National hospital costs for pulmonary mycobacterial diseases in the US from 2001 to 2012. International Journal of Mycobacteriology, 2015, 4, 156-157.	0.3	1
140	Nontuberculous Mycobacteria Isolation from Clinical and Environmental Samples in Iran: Twenty Years of Surveillance. BioMed Research International, 2015, 2015, 1-10.	0.9	19
141	Nontuberculous Mycobacteria: Epidemiologic, Mycobacteriologic, and Clinical Aspects. BioMed Research International, 2015, 2015, 1-2.	0.9	11
142	Identification and Genotyping of Mycobacterium tuberculosis Isolated From Water and Soil Samples of a Metropolitan City. Chest, 2015, 147, 1094-1102.	0.4	33
143	Hospital costs in the US for pulmonary mycobacterial diseases. International Journal of Mycobacteriology, 2015, 4, 217-221.	0.3	16
144	Metabolomics: Applications and Promise in Mycobacterial Disease. Annals of the American Thoracic Society, 2015, 12, 1278-1287.	1.5	38

#	Article	IF	CITATIONS
145	Gender susceptibility to mycobacterial infections in patients with non-CF bronchiectasis. International Journal of Mycobacteriology, 2015, 4, 92-96.	0.3	29
146	Primary sclerosing cholangitis in common variable immune deficiency. Allergology International, 2015, 64, 187-189.	1.4	12
147	Sarcoidosis in the National Veteran Population. Ophthalmology, 2015, 122, 934-938.	2.5	41
148	Association of serum TNF-α, IL-8 and free light chain with HLA-DR B alleles expression in pulmonary and extra-pulmonary sarcoidosis. Journal of Inflammation, 2015, 12, 21.	1.5	11
149	"Multidrug-resistant tuberculosis―may be nontuberculous mycobacteria. European Journal of Internal Medicine, 2015, 26, 279-284.	1.0	69
150	Nontuberculous mycobacteria in Middle East: Current situation and future challenges. International Journal of Mycobacteriology, 2015, 4, 7-17.	0.3	43
151	Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective. European Respiratory Journal, 2015, 46, 871-874.	3.1	68
152	Plasma Free Hemoglobin Is an Independent Predictor of Mortality among Patients on Extracorporeal Membrane Oxygenation Support. PLoS ONE, 2015, 10, e0124034.	1.1	117
153	Molecular Epidemiology of Nontuberculous Mycobacteria Isolates from Clinical and Environmental Sources of a Metropolitan City. PLoS ONE, 2014, 9, e114428.	1.1	38
154	Rituximab in the treatment of refractory pulmonary sarcoidosis. European Respiratory Journal, 2014, 43, 1525-1528.	3.1	133
155	Highlight on Advances in Nontuberculous Mycobacterial Disease in North America. BioMed Research International, 2014, 2014, 1-10.	0.9	51
156	Management of nontuberculous mycobacterial infection in the elderly. European Journal of Internal Medicine, 2014, 25, 356-363.	1.0	44
157	Rifampin induced angioedema: a rare but serious side effect. Brazilian Journal of Infectious Diseases, 2014, 18, 102-103.	0.3	3
158	Pneumococcal Vaccine and Patients with Pulmonary Diseases. American Journal of Medicine, 2014, 127, 886.e1.886.e8.	0.6	28
159	Nontuberculous Mycobacterial Disease Mortality in the United States, 1999–2010: A Population-Based Comparative Study. PLoS ONE, 2014, 9, e91879.	1.1	131
160	Pneumococcal Vaccines: Understanding Centers for Disease Control and Prevention Recommendations. Annals of the American Thoracic Society, 2014, 11, 980-985.	1.5	13
161	Adalimumab Induced Subcutaneous Nodular Sarcoidosis; A Rare Side Effect of Tumor Necrosis Factor-α Inhibitor. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 249-51.	0.2	7
162	Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. International Journal of Infectious Diseases, 2013, 17, e1000-e1004.	1.5	101

#	Article	IF	CITATIONS
163	Outcomes in females hospitalised with community-acquired pneumonia are worse than in males. European Respiratory Journal, 2013, 41, 1135-1140.	3.1	20
164	Multidrug-resistant tuberculosis treatment with linezolid-containing regimen. International Journal of Mycobacteriology, 2013, 2, 233-236.	0.3	5
165	After 40years, new medicine for combating TB. International Journal of Mycobacteriology, 2013, 2, 1-2.	0.3	21
166	Nonsteroidal therapy of sarcoidosis. Current Opinion in Pulmonary Medicine, 2013, 19, 516-523.	1.2	34
167	Antineutrophil Cytoplasmic Autoantibody–Associated Systemic Vasculitis is Associated With Epstein-Barr Virus in the Setting of HIV Infection. Infectious Diseases in Clinical Practice, 2013, 21, 50-53.	0.1	12
168	Personalized medicine approach in mycobacterial disease. International Journal of Mycobacteriology, 2012, 1, 59-64.	0.3	8
169	Generalized lymphadenopathy with cystic spleen lesions: a rare presentation of tuberculosis. International Journal of Infectious Diseases, 2011, 15, e505.	1.5	Ο
170	Association Between Time to Clinical Stability and Outcomes After Discharge in Hospitalized Patients With Community-Acquired Pneumonia. Chest, 2011, 140, 482-488.	0.4	41
171	Utility of gastric lavage for diagnosis of tuberculosis in patients who are unable to expectorate sputum. Journal of Clobal Infectious Diseases, 2011, 3, 339.	0.2	15
172	Outcome of Nursing Home Associated Pneumonia in African American Hospitalized Patients. Chest, 2011, 140, 763A.	0.4	0
173	Thrombocytopenia and Thrombocytosis at Time of Hospitalization Predict Mortality in Patients With Community-Acquired Pneumonia. Chest, 2010, 137, 416-420.	0.4	129
174	Thrombocytosis in Patients With Severe Community-Acquired Pneumonia: Response. Chest, 2010, 138, 1279-1280.	0.4	1
175	Predicting Mortality in Patients with Ventilatorâ€Associated Pneumonia: The APACHE II Score versus the New IBMPâ€10 Score. Clinical Infectious Diseases, 2009, 49, 72-77.	2.9	32
176	Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study. Scandinavian Journal of Infectious Diseases, 2009, 41, 10-13.	1.5	7
177	First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran—eight years of surveillance. International Journal of Infectious Diseases, 2009, 13, e236-e240.	1.5	69
178	Nontuberculous Mycobacteria Among Patients Who are Suspected for Multidrug-Resistant Tuberculosis—Need for Earlier Identification of Nontuberculosis Mycobacteria. American Journal of the Medical Sciences, 2009, 337, 182-184.	0.4	35
179	The NRAMPI, VDR and TNF-α gene polymorphisms in Iranian tuberculosis patients: the study on host susceptibility. Brazilian Journal of Infectious Diseases, 2009, 13, 252-6.	0.3	69
180	The Recent-Transmission of Mycobacterium tuberculosis Strains among Iranian and Afghan Relapse Cases: a DNA-fingerprinting using RFLP and spoligotyping. BMC Infectious Diseases, 2008, 8, 109.	1.3	43

#	Article	IF	CITATIONS
181	Representative drug susceptibility patterns for guiding design of reâ€ŧreatment regimens for multidrugâ€resistant tuberculosis in Iran. Respirology, 2008, 13, 108-111.	1.3	5
182	Acute Myocardial Infarction in Hospitalized Patients with Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2008, 47, 182-187.	2.9	166
183	Incidence, Etiology, Timing, and Risk Factors for Clinical Failure in Hospitalized Patients With Community-Acquired Pneumonia. Chest, 2008, 134, 955-962.	0.4	112
184	Instability of IS6110 patterns in multidrug-resistant strains of Mycobacterium tuberculosis. Epidemiology and Infection, 2007, 135, 346-352.	1.0	10
185	Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiology and Drug Safety, 2007, 16, 1104-1110.	0.9	43
186	Multi-drug Resistant Tuberculosis in Pregnancy: Need for More Intensive Treatment. Infection, 2007, 35, 477-478.	2.3	12
187	The most prevalent Mycobacterium tuberculosis superfamilies among Iranian and Afghan TB cases. Scandinavian Journal of Infectious Diseases, 2006, 38, 463-468.	1.5	36
188	Lack of association between interferonâ€gamma receptorâ€1 polymorphism and pulmonary TB in Iranian population sample. Journal of Infection, 2006, 52, 374-377.	1.7	14
189	Chronic Granulomatous Disease with Unusual Clinical Manifestation, Outcome, and Pattern of Inheritance in an Iranian Family. Journal of Clinical Immunology, 2006, 26, 291-296.	2.0	12
190	Prevalence of Haarlem I and Beijing types of Mycobacterium tuberculosis strains in Iranian and Afghan MDR-TB patients. Journal of Infection, 2006, 53, 331-336.	1.7	60
191	Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nature Genetics, 2005, 37, 692-700.	9.4	198
192	Inherited disorders of the IL-12-IFN-Î ³ axis in patients with disseminated BCG infection. European Journal of Pediatrics, 2005, 164, 753-757.	1.3	59
193	Primary Immune Deficiencies Presenting in Adults: Seven Years of Experience from Iran. Journal of Clinical Immunology, 2005, 25, 385-391.	2.0	28
194	Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. International Journal of Infectious Diseases, 2005, 9, 317-322.	1.5	44
195	Application of Oxidation-Reduction Assay for Monitoring Treatment of Patients with Pulmonary Tuberculosis. Journal of Clinical Microbiology, 2004, 42, 3324-3325.	1.8	22
196	Bacteriological follow-up of pulmonary tuberculosis treatment: a study with a simple colorimetric assay. Microbes and Infection, 2004, 6, 972-976.	1.0	10
197	Association of COVID-19 Case-Fatality Rate With State Health Disparity in the United States. Frontiers in Medicine, 0, 9, .	1.2	3